Magnetoencephalography as a Biomarker for HIV-Associated Neurocognitive Disorder

脑磁图作为 HIV 相关神经认知障碍的生物标志物

基本信息

批准号：
8469618
负责人：
JAMES T. BECKER
金额：
$ 22.02万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-09-21 至 2014-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8469618
关键词：
AIDS Dementia Complex AIDS neuropathy Activities of Daily Living Address Affect Area Automobile Driving Biological Biological Markers Brain Caring Cerebrovascular Circulation Chronic Clinical Cognition Cognition Disorders Cognitive Cognitive deficits Country Data Dementia Development Differential Diagnosis Disease Emerging Technologies Employment Enrollment Epilepsy Exploratory/Developmental Grant Eye Functional Magnetic Resonance Imaging Functional disorder Funding Goals HIV Image Impaired cognition Individual Life Longitudinal Studies MRI Scans Magnetic Resonance Imaging Magnetoencephalography Measures Medical Methods Modality Modeling Morphologic artifacts Movement Neurocognitive Neurons Neuropsychological Tests Outcome Participant Pathology Patients Performance Physiologic pulse Pilot Projects Population Positron-Emission Tomography Price Publishing Recovery Relative (related person)Research Research Project Grants Resolution Rest Scanning Screening procedure Secondary to Series Signal Transduction Signs and Symptoms Spin Labels Study Subject Synapses Techniques Technology Testing Therapeutic Woman base blood oxygen level dependent design imaging modality magnetic field medication compliance meetings memory recognition neurobehavioral neuroimaging neuropsychological novel research clinical testing response tool volunteer white matter damage

项目摘要

DESCRIPTION (provided by applicant): HIV disease is becoming more of a chronic condition in countries with good access to medical care. In the area of NeuroAIDS there is no acknowledged, useful biomarker for the cognitive disorder associated with HIV disease (i.e., HIV-Associated Neurocognitive Disorder (HAND)), independent of the cognitive tests. Magnetic resonance imaging and positron emission tomography have been tried, but have yet to fulfill their promise {Price, 2007 #6509}. One emerging technology that has only recently been applied to HIV Disease - by our research team - is magnetoencephalography (MEG). MEG is a non-invasive technique for measuring neuronal activity by recording the magnetic fields induced by synchronized neuronal currents. MEG has the highest spatial and temporal resolution of any current neuroimaging technology, and is used most commonly in the clinical evaluation of patients with seizure disorders, and by cognitive neuroscientists to investigate electrophysiological responses of the CNS. Unlike techniques such as functional MRI, MEG does not rely on the blood-oxygen level dependent response in order to generate responses. Thus, it will be very important to determine whether MEG can identify abnormal brain function in HIV Disease - especially when cognitive dysfunction is mild and not yet affecting activities of daily living. Our team has demonstrated that we can differentiate infected from uninfected study subjects, that there may be an independent MEG-derived variable that is sensitive to cognitive dysfunction, and that MEG signals are stable over a 6-month period. The preliminary research was conducted in the context of an R03-funded study, so the overall goal of this new R21 research project is to obtain the necessary additional data from 30 infected individuals (and 10 controls) to finalize the design for a larger, longitudinal study. These data will allow us to begi to characterize the neurocognitive outcomes of HIV Disease using a highly sensitive electrophysiological tool. PUBLIC HEALTH RELEVANCE: HIV infected patients can still have abnormalities in cognition ranging from the more common mild deficits, to the less common, but more devastating dementia. What is missing in the field of NeuroAIDS is a tool that will provide information about the biological state of the brain that is related to the cognitive impairment. We propose to study Magnetoencephalography (MEG) as a potential biomarker. In this project, we will find out whether it is feasible to use MEG in patients with NeuroAIDS, and we will decide exactly how to design a larger, longitudinal study.

描述（由申请人提供）：在医疗保健条件良好的国家，艾滋病毒越来越成为一种慢性疾病。在神经艾滋病领域，与艾滋病毒疾病相关的认知障碍（即艾滋病毒相关神经认知障碍（HAND））没有公认的、有用的生物标志物，独立于认知测试。磁共振成像和正电子发射断层扫描已经尝试过，但尚未兑现其承诺{Price，2007 #6509}。我们的研究团队最近才将一项新兴技术应用于 HIV 疾病，即脑磁图 (MEG)。 MEG 是一种通过记录同步神经元电流感应的磁场来测量神经元活动的非侵入性技术。 MEG 具有当前所有神经影像技术中最高的空间和时间分辨率，最常用于癫痫症患者的临床评估，以及认知神经科学家研究中枢神经系统的电生理反应。与功能性 MRI 等技术不同，MEG 不依赖于血氧水平依赖性反应来产生反应。因此，确定 MEG 是否可以识别 HIV 疾病中的异常脑功能非常重要，特别是当认知功能障碍较轻且尚未影响日常生活活动时。我们的团队已经证明，我们可以区分感染者和未感染者，可能存在一个对认知功能障碍敏感的独立 MEG 衍生变量，并且 MEG 信号在 6 个月内保持稳定。初步研究是在 R03 资助的研究背景下进行的，因此这个新的 R21 研究项目的总体目标是从 30 名感染者（和 10 名对照者）获得必要的额外数据，以最终确定更大、纵向的设计。学习。这些数据将使我们能够开始使用高度敏感的电生理学工具来描述艾滋病毒疾病的神经认知结果。公共卫生相关性：艾滋病毒感染者仍然可能出现认知异常，从更常见的轻度缺陷到不太常见但更具破坏性的痴呆。 NeuroAIDS 领域缺少的是一种能够提供与认知障碍相关的大脑生物状态信息的工具。我们建议研究脑磁图（MEG）作为潜在的生物标志物。在这个项目中，我们将找出在 NeuroAIDS 患者中使用 MEG 是否可行，并且我们将决定如何设计更大规模的纵向研究。